Combinations and modes of administration of therapeutic agents and combination therapy

Abstract

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

1 - 41 . (canceled) 
     
     
         42 : A single composition comprising: (a) nanoparticles comprising paclitaxel and albumin and (b) an anti-VEGF antibody, wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is between 0.01:1 and 100:1, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nM, wherein the nanoparticles comprise paclitaxel coated with albumin. 
     
     
         43 : The composition of  claim 42 , wherein the anti-VEGF antibody is bevacizumab. 
     
     
         44 : The composition of  claim 42 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 30:1. 
     
     
         45 : The composition of  claim 42 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 10:1. 
     
     
         46 : The composition of  claim 43 , wherein the weight ratio of the paclitaxel and the bevacizumab is less than about 10:1. 
     
     
         47 : The composition of  claim 42 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is about 2:1 to about 3:1. 
     
     
         48 : The composition of  claim 43 , wherein the weight ratio of the paclitaxel and the bevacizumab is about 2:1 to about 3:1. 
     
     
         49 : The composition of  claim 42 , wherein the composition further comprises a platinum-based agent. 
     
     
         50 : The composition of  claim 49 , wherein the platinum-based agent is carboplatin. 
     
     
         51 : The composition of  claim 42 , wherein the nanoparticles comprise paclitaxel coated with albumin. 
     
     
         52 : The composition of  claim 42 , wherein the weight ratio of albumin to paclitaxel in the composition is 9:1 or less. 
     
     
         53 : The composition of  claim 42 , further comprising saline. 
     
     
         54 : The composition of  claim 42 , further comprising a pharmaceutically acceptable excipient.